[Intravitreal ganciclovir in cytomegalovirus retinitis in AIDS]. 1996

J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
Servicio de OftalmologĂ­a, Hospital Son Dureta, Palma de Mallorca.

A retrospective study was made of 26 patients with AIDS who initially presented with retinitis as the only clinical manifestation of cytomegalovirus infection (39 eyes). Sixty-five induction or re-induction therapeutic courses were administered with intravitreal ganciclovir. The efficiency rate of therapy was 93.8%. Thirty-eight maintenance therapeutic courses (200 micrograms/week) were evaluated. The non-compliance rate was 23%. Bilateral retinitis occurred in 44.4% of cases. The systemic administration of therapy had to be substituted for the intravitreal administration in 32% of patients during the clinical course of their conditions. The mean survival rate was 9.5 months. Both retinal detachment and vitreal hemorrhage occurred in 5% of patients. When retinitis is the first clinical manifestation of cytomegalovirus infection, therapy with intravitreal ganciclovir is efficacious to inactivate lesions. Although bilateral retinitis and extraocular dissemination are common, the mean survival rate is high.

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D008297 Male Males
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective

Related Publications

J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
January 1992, The Annals of pharmacotherapy,
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
January 1996, The Annals of pharmacotherapy,
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
January 1990, Presse medicale (Paris, France : 1983),
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
August 1996, Nippon Ganka Gakkai zasshi,
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
November 2005, Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
May 1988, Ophthalmology,
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
April 1998, International journal of STD & AIDS,
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
August 1990, The British journal of ophthalmology,
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
April 2010, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie,
J L Olea, and M Salvat, and J M Mateos, and J Vila, and C Villalonga, and M Riera
March 1998, The British journal of ophthalmology,
Copied contents to your clipboard!